TMCnet News
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the company granted a newly hired executive an option to purchase 130,000 shares of the company's common stock with a per share exercise price of $8.61, the closing price on the grant date. These options will vest as to 25% of the total number of shares subject to the option on the first anniversary of the grant date. The remaining 75% of shares will vest ratabl on the first day of each calendar quarter over the next three years. The stock options were inducements material to the new employee entering into employment with the company, and issued in reliance on NASDAQ Listing Rule 5635(c)(4).
About Akebia Therapeutics
View source version on businesswire.com: http://www.businesswire.com/news/home/20161202005531/en/ |